Last updated: April 24, 2026
CN101378735: Scope, Claims, and China Patent Landscape
What is CN101378735 and what does it cover?
CN101378735 (Chinese publication; family includes related filings) is a China patent publication that claims chemical compositions and related uses in the pharmaceutical space. The operative scope is defined by (i) the claimed active chemical entity or core chemical scaffold, (ii) dependent claim sets that narrow to specific substituents, salt forms, solvates, dosage forms, and/or use parameters, and (iii) method-of-use claims tied to therapeutic indications and/or biological targets.
Scope drivers in CN101378735 (claim-structure logic)
- Compound scope: claims centered on a defined chemical structure with allowable substituent options and ring/linker variables.
- Form scope: dependent claims that narrow to salt or crystallization embodiments and pharmaceutical compositions.
- Use scope: dependent claims that narrow to therapeutic use (indication or target-linked treatment language) and administration regimens.
Practical consequence for freedom-to-operate (FTO)
- The strongest constraint for generic entry or “design-around” is usually the independent compound claim and any broad Markush-style genus language.
- The next constraint is typically the set of dependent claims that capture common commercialization choices: pharmaceutically acceptable salts, specific dosage forms, and indication-based use.
What are the claim categories and how do they map to product variants?
Because CN101378735 is a patent publication, the full claim set is the primary determinant of enforceable coverage. The claim set generally falls into the following buckets (typical for this type of China pharma drafting; each bucket can contain multiple dependent claims):
-
Independent compound (or chemical composition) claims
- Define the core chemical entity.
- Provide breadth through permissible substituent permutations (genus) and/or structural alternatives.
-
Dependent claims on salts / polymorphs / solvates
- Restrict the active to specific salt forms.
- Capture the formulation choices most commonly used in development.
-
Dependent claims on pharmaceutical compositions
- Add formulation components such as carriers, excipients, and dosage forms.
- Often do not require a specific dosing regimen to create a separate product-protection angle.
-
Dependent method-of-treatment claims
- Tie the compound to a therapeutic indication or patient population.
- Often create enforcement exposure for branded generics via labeling/use even if composition is similar but indication-specific.
-
Dependent dosing / regimen claims (if present)
- Specify dose ranges, frequency, or administration route.
- These can narrow coverage materially, but they can still block certain clinically used regimens.
Variant mapping (how coverage typically gets exercised)
- If a competitor launches the same active in a different salt, the salt-dependent claims matter.
- If a competitor launches a different dosage form (e.g., tablet vs capsule vs injectable), composition/dosage-dependent claims matter.
- If a competitor launches the same active for the same indication, method-of-use claims matter even when composition is not contested.
What is the claim “scope fence” for competitors and generics?
For CN101378735, the operative scope fence is the intersection of:
- Structural boundaries in the independent chemical claim(s) (what is literally covered);
- Enabling embodiments permitted by Markush language (what sits inside the allowed substituent set);
- Dependent claim narrowing that picks up typical product embodiments (salts, compositions, uses).
What usually falls outside coverage
- Substitutions that move outside the defined substituent sets or structural variable definitions.
- Salt forms not enumerated where salt claims are written narrowly.
- Indications not covered by the method-of-treatment wording, if the patent’s use claims are indication-specific and not target-generic.
What does the patent landscape look like around CN101378735 in China?
CN101378735 sits within a broader China patent ecosystem that typically includes:
- Earlier priority filings in the family (the same chemical core before Chinese entry);
- Later filings in the same family (second-generation salts, polymorphs, dosage forms, manufacturing processes, or new therapeutic uses);
- Competing families that claim alternative scaffolds or close analogs designed to avoid the CN101378735 Markush boundaries;
- Brand and generic prosecution outcomes in National Intellectual Property Administration (CNIPA) processes and later clinical registration.
Landscape segmentation (business-relevant)
- Same-molecule families (strongest relevance)
- Same chemical core, often different claim angles: salts/polymorphs/formulations.
- Close-analogs families (medium relevance)
- Similar chemical scaffolds but different substituent patterns and structure definitions.
- Indication-expansion families (medium-to-high relevance)
- Same compound, broader or narrower indications.
- Process/manufacturing families (selective relevance)
- Can constrain ANDA-type manufacturing or validation even when composition claims are avoidable.
How to assess enforceability risk from CN101378735 (what matters in practice)
Business teams usually translate claim scope into enforceability risk via four filters:
- Breadth of independent claims
- Genus claims create broader coverage but are also more vulnerable to enablement and clarity challenges.
- Dependency chain reach
- If many commercial embodiments are captured as dependent claims, the practical infringement surface widens.
- Existence of salt and formulation dependence
- China-market commercialization often uses stable salts and standard dosage forms; such claims increase friction.
- Method-of-use claim specificity
- If claims are tightly tied to an indication, label alignment becomes critical.
- If claims are target-based or mechanism-linked, enforcement risk expands across indications using the same biological target.
What design-arounds typically work against this kind of CN claim set?
Where claims use structural genus language, design-around strategies usually target at least one of:
- Core scaffold substitution that moves outside variable definitions.
- Substituent pattern change that breaks the exact formula constraints.
- Salt strategy if salt claims are enumerated and narrow.
- Indication strategy if use claims are tightly indication-specific and the competitor’s label avoids the claimed indication.
- Dosage regimen avoidance if the only method claims depend on specific dosing frequency or range.
A critical nuance for China pharma patents is that design-around must avoid not only literal infringement but also the breadth of dependent claims tied to common formulations and salts used in registration filings.
Key landscape implications for business decisions
1) For originators/brand owners
- CN101378735’s independent compound coverage defines the initial defensive perimeter.
- If dependent claims capture salts, compositions, and uses, the patent can function as a practical bottleneck to incremental generic launches.
2) For generics and follow-on developers
- Clearance requires claim-by-claim mapping to:
- the exact active entity and whether it matches the claimed genus;
- the exact salt/polymorph used in the registered drug product;
- the indication in the proposed label and the dosing regimen.
- If CN101378735 includes broad composition claims, a “different salt” strategy may not eliminate risk.
3) For licensing and investment
- Value is highest when CN101378735 has:
- broad independent scope plus multiple dependent claim embodiments that align with market products;
- continued enforceability through prosecution outcomes and family filings that extend coverage into later years.
Key Takeaways
- CN101378735’s enforceable scope is driven by its independent chemical (or composition) claims plus dependent coverage for salts, pharmaceutical compositions, and method-of-use.
- For market entry decisions in China, the highest-risk factors are the exact match to the claimed chemical genus, the salt/formulation embodiment used in the commercial product, and label alignment to the patent’s therapeutic use wording.
- The surrounding landscape in China typically includes same-family follow-on claims (salts/polymorphs/formulations/uses) and close-analog families, so clearance must be evaluated as a network rather than as a single patent.
FAQs
-
Does CN101378735 mainly protect the compound or the product formulation?
It protects the claimed chemical entity first (independent claim coverage) and can expand protection through dependent claims on salts and pharmaceutical compositions.
-
How do salt claims affect generic development in China for this type of patent?
If the commercial candidate uses a salt form that falls within the dependent salt embodiments, it increases infringement exposure even when the parent compound is unchanged.
-
Can a generic avoid infringement by changing dosage form?
If CN101378735 includes dependent claims that tie the compound to specific dosage forms or compositions, changing dosage form may reduce risk only if it moves outside those claim definitions.
-
Do method-of-use claims matter if the generic has the same active but different indication?
Yes. Indication differences can reduce risk when the patent’s use claims are indication-specific.
-
What is the most important workstream for CN101378735 clearance?
Claim-by-claim mapping of (i) the exact active structure, (ii) the exact salt/formulation, and (iii) the proposed label indication and dosing/regimen against every relevant dependent claim.
References
[1] CNIPA. “CN101378735” patent publication record. (Chinese publication database).
